LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

52.81 4.18

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

50.09

Max

53.62

Galvenie mērījumi
By Trading Economics
Ienākumi	-68M -45M
Pārdošana	27M 192M
P/E Sektora vidējais	48.435 108.767
Peļņas marža	-23.486
Darbinieki	674
EBITDA	-75M -37M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+16.64% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-217M 2.9B
Iepriekšējā atvēršanas cena	48.63
Iepriekšējā slēgšanas cena	52.81

Ziņu noskaņojums

By Acuity

41%

59%

137 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. febr. 23:07 UTC

Peļņas

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 23:01 UTC

Peļņas

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:59 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026. g. 24. febr. 22:42 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026. g. 24. febr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026. g. 24. febr. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026. g. 24. febr. 23:36 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026. g. 24. febr. 23:30 UTC

Tirgus saruna

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. febr. 23:16 UTC

Peļņas

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026. g. 24. febr. 23:13 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026. g. 24. febr. 23:12 UTC

Peļņas

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026. g. 24. febr. 23:08 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026. g. 24. febr. 23:07 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026. g. 24. febr. 22:52 UTC

Peļņas

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 22:46 UTC

Peļņas

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:31 UTC

Iegādes, apvienošanās, pārņemšana

Warner Receives New Bid From Paramount -- 3rd Update

2026. g. 24. febr. 22:29 UTC

Peļņas

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026. g. 24. febr. 22:28 UTC

Peļņas

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026. g. 24. febr. 22:25 UTC

Peļņas

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026. g. 24. febr. 22:24 UTC

Peļņas

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026. g. 24. febr. 22:23 UTC

Peļņas

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths Interim Dividend 45 Australian Cents/Share

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026. g. 24. febr. 22:21 UTC

Peļņas

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

16.64% augšup

Prognoze 12 mēnešiem

Vidējais 62.17 USD 16.64%

Augstākais 65 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

137 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.